Erythromycin-associated cholestatic hepatitis. Derby, L. E.; Jick, H.; Henry, D. A.; and Dean, A. D. The Medical Journal of Australia, 158(9):600--602, May, 1993.
abstract   bibtex   
OBJECTIVE: To estimate the risk of cholestatic hepatitis of uncertain origin in patients who had recently received erythromycin, a drug which is known to cause this disorder. DESIGN: A retrospective cohort study using data automatically recorded on general practitioners' office computers. SETTING: Some 600 general practices in the United Kingdom. SUBJECTS: 366,064 people who received erythromycin. MAIN OUTCOME MEASURE: Clinically documented cholestatic hepatitis of uncertain origin diagnosed 1-45 days after a prescription for erythromycin. RESULTS: There were 13 cases of cholestatic hepatitis of uncertain origin diagnosed within 45 days of receiving erythromycin which were either characteristic of or consistent with a syndrome previously described as being associated with this drug. CONCLUSION: The risk of cholestatic jaundice associated with erythromycin is estimated to be in the range of 3.6 per 100,000 users (95% confidence interval, 1.9-6.1).
@article{derby_erythromycin-associated_1993,
	title = {Erythromycin-associated cholestatic hepatitis},
	volume = {158},
	issn = {0025-729X},
	abstract = {OBJECTIVE: To estimate the risk of cholestatic hepatitis of uncertain origin in patients who had recently received erythromycin, a drug which is known to cause this disorder.
DESIGN: A retrospective cohort study using data automatically recorded on general practitioners' office computers.
SETTING: Some 600 general practices in the United Kingdom.
SUBJECTS: 366,064 people who received erythromycin.
MAIN OUTCOME MEASURE: Clinically documented cholestatic hepatitis of uncertain origin diagnosed 1-45 days after a prescription for erythromycin.
RESULTS: There were 13 cases of cholestatic hepatitis of uncertain origin diagnosed within 45 days of receiving erythromycin which were either characteristic of or consistent with a syndrome previously described as being associated with this drug.
CONCLUSION: The risk of cholestatic jaundice associated with erythromycin is estimated to be in the range of 3.6 per 100,000 users (95\% confidence interval, 1.9-6.1).},
	language = {eng},
	number = {9},
	journal = {The Medical Journal of Australia},
	author = {Derby, L. E. and Jick, H. and Henry, D. A. and Dean, A. D.},
	month = may,
	year = {1993},
	pmid = {8479375},
	keywords = {Adolescent, Adult, Aged, Aged, 80 and over, Child, Cholestasis, Cohort Studies, Drug-Induced Liver Injury, Erythromycin, Female, Humans, Male, Middle Aged, Retrospective Studies},
	pages = {600--602}
}
Downloads: 0